Glimepiride Zentiva

Glimepiride Zentiva is a prescription oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea used for managing blood glucose. It is marketed in the European Union and is supplied in tablet form, although specific strength and dosage form details are not disclosed here. The product belongs to the antidiabetic, oral hypoglycemic therapeutic class.

Glimepiride Zentiva is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It may be used in combination with diet, exercise, and other antidiabetic agents when needed.

- Improves glycemic control in adults with type 2 diabetes. - Used as monotherapy when metformin is contraindicated. - Can be combined with metformin or other oral agents. - May be added to insulin therapy for additional glucose lowering. - Supports long‑term management of hyperglycemia alongside lifestyle measures.

Glimepiride Zentiva may cause a range of side effects, some of which are more frequent than others. Patients should be aware of both common and serious reactions.

Common: - Mild hypoglycemia, especially with missed meals. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as rash or angioedema. - Hepatic dysfunction indicated by jaundice or elevated liver enzymes.

Before starting Glimepiride Zentiva, several precautionary measures should be considered to ensure safe use.

- Assess renal and hepatic function prior to initiation. - Monitor blood glucose regularly to detect hypoglycemia. - Use cautiously in elderly patients who may be more susceptible to low blood sugar. - Avoid use during pregnancy or breastfeeding unless clearly indicated. - Review all concomitant medications for potential interactions. - Educate patients on recognizing and managing hypoglycemic episodes.

Glimepiride Zentiva can interact with various drugs, affecting its efficacy or safety profile. Understanding these interactions helps optimize therapy.

Avoid: - Other sulfonylureas or insulin secretagogues that may increase hypoglycemia risk. - Strong CYP2C9 inhibitors (e.g., fluconazole) that raise glimepiride levels. - High‑dose aspirin or NSAIDs that may potentiate hypoglycemia.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may affect glucose control. - Antifungal agents like ketoconazole that modestly increase drug exposure.